SCHEMBL3603369

SCHEMBL3603369

Nc1nnc(N2CCC(O)CC2)s1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.69
MAPK1 P28482 3/20 0.69
HPGD P15428 3/20 0.69
KDM4E B2RXH2 1/20 0.69
NPC1 O15118 1/20 0.69
TSHR P16473 1/20 0.69
RAB9A P51151 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
GAA P10253 2/20 0.61
HSD17B10 Q99714 1/20 0.61
GFER P55789 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
HRH3 Q9Y5N1 3/20 0.43
GLS O94925 6/20 0.40
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
OGA O60502 1/20 0.36
SMARCA2 P51531 1/20 0.35
SMARCA4 P51532 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17654176 0.82 ALDH1A1 (0.79) ALDH1A1MAPK1HPGDKDM4ENPC1
SCHEMBL8132450 0.81 ALDH1A1 (1.00) ALDH1A1MAPK1HPGDKDM4ENPC1
SCHEMBL3601230 0.79 HRH3 (0.44) ALDH1A1MAPK1HPGDKDM4ENPC1
SCHEMBL18006604 0.78 ALDH1A1 (0.64) ALDH1A1MAPK1HPGDKDM4ENPC1
SCHEMBL5199794 0.78 ALDH1A1 (0.96) ALDH1A1MAPK1HPGDKDM4ENPC1
SCHEMBL12177990 0.78 HRH3 (0.49) ALDH1A1MAPK1HPGDKDM4ENPC1
SCHEMBL18006623 0.77 ALDH1A1 (0.68) ALDH1A1MAPK1HPGDKDM4ENPC1
SCHEMBL5631018 0.76 ALDH1A1 (1.00) ALDH1A1MAPK1HPGDKDM4ENPC1
SCHEMBL11372459 0.76 ALDH1A1 (1.00) ALDH1A1MAPK1HPGDKDM4ENPC1
SCHEMBL17654100 0.76 ALDH1A1 (0.84) ALDH1A1MAPK1HPGDKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004245-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2010-01-07 US disclosed
EP-2076509-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE Merck Frosst Canada Ltd. (CA) 2009-07-08 EP disclosed
WO-2008046226-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004245-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE SCD, SCD5, SREBF1 ALDH1A1 400/4885MAPK1 1248/4885HPGD 1495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.